Skip to Content

Probuphine Approval Status

  • FDA approved: No
  • Brand name: Probuphine
  • Generic name: buprenorphine
  • Company: Titan Pharmaceuticals, Inc.
  • Treatment for: Opiate Dependence

Probuphine (buprenorphine) is an opioid partial agonist subdermal implant in development for the treatment of opioid dependence.

Development Status and FDA Approval Process for Probuphine

Feb 19, 2016Titan Pharmaceuticals Announces Notification of FDA Action Date Extension for Probuphine
Jan 12, 2016Titan Pharmaceuticals And Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval Of Probuphine
Sep 28, 2015Titan Pharmaceuticals Announces FDA's Acceptance of Resubmission of NDA for Probuphine
Jun  8, 2015Titan Pharmaceuticals Reports Positive Results from Phase 3 Study of Probuphine for Opioid Addiction
May  1, 2013Titan Pharmaceuticals Receives Complete Response Letter From the FDA for Probuphine New Drug Application
Feb 27, 2013Titan Pharmaceuticals Announces Date of FDA Advisory Committee Review of Probuphine for the Treatment of Opioid Dependence
Oct 29, 2012Titan Pharmaceuticals Announces Submission of New Drug Application for Probuphine for the Treatment of Opioid Dependence

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.